Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2025 08:36 ET | Source: SeaStar Medical

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

Data show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending to 90 days DENVER, Sept. 29, 2025 (GLOBE...
September 24, 2025 16:22 ET | Source: SeaStar Medical

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE)...
September 23, 2025 08:23 ET | Source: SeaStar Medical

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE...
September 04, 2025 18:13 ET | Source: SeaStar Medical

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients...
September 02, 2025 08:22 ET | Source: SeaStar Medical

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

IJME publication of QUELIMMUNE therapy for pediatric AKI shows a potential for hospitals to incur no out-of-pocket costs for 6 days of treatment.
August 13, 2025 16:05 ET | Source: SeaStar Medical

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolledThree new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute...
August 07, 2025 10:00 ET | Source: SeaStar Medical

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients...
August 06, 2025 08:33 ET | Source: SeaStar Medical

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

Trial now over 60% enrolled with 125 of 200 anticipated patients Recent new site activation brings total clinical trial sites to 16 Interim analysis of first 100 patients remains on track for 3Q...
July 31, 2025 15:01 ET | Source: SeaStar Medical

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients...
July 22, 2025 08:20 ET | Source: SeaStar Medical

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

DENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE...